Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2010

View Archived Issues

FDA approves folate-containing oral contraceptive Safyral

UCB claims new PI3K inhibitors

ClanoTech divulges new inhibitors of VEGFR-2 and VEGFR-3

Panobinostat/capecitabine/lapatinib combination is safe in HER2+ breast cancer

Clinical and preclinical data presented on GDC-0941/T-DM1 in HER2+ breast cancer

NS-018 preferentially targets V617F-mutant JAK2

MRx-102 shows promise in models of AML

Enrollment complete in phase IIb COMPONENT trial of vidofludimus in RA

EMA's CHMP recommends approval of Esbriet for IPF

Janssen submits European MAA for telaprevir in chronic hepatitis C

FDA grants fast track status for elacytarabine in AML

Lpath enters into an option license agreement with Pfizer for iSONEP

EMA provides update on safety review for somatropin-containing medicines

Bristol-Myers Squibb and Oncolys sign licensing agreement for festinavir

Manhattan Pharma reports preliminary phase I/II data on AST-915

Scientists identify new susceptibility loci for Hodgkin's lymphoma

GSK and Impax collaborate on late-stage Parkinson's disease therapeutic

New selective JAK1 inhibitors disclosed by Incyte

Idera Pharma reports phase I data on IMO-2125 in hepatitis C

Willfact to be launched in additional European countries

Bayer and Regeneron report topline phase III data on VEGF Trap-Eye

Gilead Sciences acquires Arresto Biosciences

New inhibitors CK II and/or pim-1 discovered at Cylene Pharma

New inhibitors of Aurora kinase A and B presented

Tasigna approved in Japan for newly diagnosed Ph+ CML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...